EverQuote
EVER
19.39
0.00
0.00%
EverQuote
US · EVER
#3533 by market cap
Listed 2018
19.39
0.00
0.00%
Live - 5344 symbols - heartbeat 221s ago
· 2026-10-08 04:38
Pre-market
19.39
0.00%
After-hours
19.39
0.00%
- Market cap
- 683.30M
- P/E (TTM)i
- 6.32
- P/Bi
- 2.66
- EPSi
- 2.63
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on EVER?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Company notice
AEON Fantasy: First-ever store in the Northeast Tohoku region! The indoor children's playground themed around the Earth, "Chikyū no Niwa Morioka," will open on Wednesday, October 7 at AEON MALL Morioka.JPX · 2026/9/7
-
Japan's stock market undergoes its largest-ever Topix restructuring: nearly 700 companies are being delisted, and trillions of dollars in passive investment funds face recalibration.Market Newswire · 2026/10/8
-
Rating change
Meikolando (600882): Q2 profit elasticity significantly unleashed; first-ever interim dividend declared.Everbright Securities · 2026/8/22
-
Accenture Stock Is Heading for Its Best Day Ever. AI Isn't the Threat Everyone Thought. -- Barrons.comBarron's · 2026/10/1
-
Rating change
EverQuote (EVER) Receives a Buy From B. Riley SecuritiesTipRanks · 2026/9/24
-
Company notice
PR TIMES: Former Head of Communications at SpaceX, Google, and Facebook to deliver Japan's first-ever keynote address! What does public relations look like in the AI era? PR TIMES College set to take place.JPX · 2026/8/28
-
Rating change
J.P. Morgan Maintains EverQuote(EVER.US) With Buy Rating, Raises Target Price to $29Market Newswire · 2026/8/24
-
Company notice
Technologies: Announcement of the first-ever nationwide live broadcast on terrestrial television for kickboxing in 16 years, along with the launch of a new regular program.JPX · 2026/9/14
-
Rating change
Lianlong (300596): Q2 2026 posted its highest-ever quarterly profit, while advancing its global production capacity deployment and expanding into new business areas.Everbright Securities · 2026/8/18
-
Why This Biotech Stock Is Having Its Worst Day Ever -- Barrons.comBarron's · 2026/10/6
-
Rating change
COFCO Jiajiakang (01610.HK): Fresh‑food business posts its first-ever profit; farming costs improve month by month.CICC · 2026/8/27
-
Rating change
B. Riley Securities Maintains EverQuote(EVER.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/9/24
-
Rating change
Alibaba-W (09988.HK): Cloud business maintains strong momentum; first-ever placement of HK$80 billion to boost AI infrastructure.Zheshang Securities · 2026/8/26
-
Rating change
Mixue Group (02097.HK): Single-store performance under pressure; first-ever special dividend distributed.Shenwan Hongyuan Research · 2026/8/31
-
Company notice
Hibino: aespa's concert at the Gocheok Sky Dome will be live-streamed on "JUUQX," marking Korea's first-ever cinema live‑viewing experience in 4K and Dolby Atmos.JPX · 2026/9/9
-
Rating change
China Taiping Insurance (601601) – 2026 Interim Report Commentary: First-ever interim dividend payout; both asset and liability sides remain relatively stable.Guolian Minsheng Securities · 2026/8/27
-
Company notice
JinkoSolar: List of First-Ever Grantees under JinkoSolar Co., Ltd.'s 2026 Restricted Stock Incentive PlanSZSI · 2026/9/29
-
Has the "strongest-ever" weight-loss drug arrived? An Eli Lilly and Co. trial shows that the combination therapy resulted in a 23% weight loss over 48 weeks, far surpassing the efficacy of monotherapy.wallstreetcn · 2026/10/1
-
Rating change
Zelgen Pharmaceuticals (688266): Licensing revenue and product volume growth drive first-ever semi-annual profitability; innovative pipeline accelerates.Tianfeng Securities · 2026/9/27
-
Lippo China Resources (00156.HK) saw its ordinary share holdings increased by 2.992 million shares, valued at approximately HK$3.968 million, by Ever Media Limited and related parties.Market Newswire · 2026/10/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 04:38:51 · For reference only, not investment advice and not tailored to your situation.